Medpace Holdings, Inc. $MEDP is Riverbridge Partners LLC’s 8th Largest Position

Riverbridge Partners LLC reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 13.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 237,407 shares of the company’s stock after selling 35,562 shares during the period. Medpace comprises about 2.8% of Riverbridge Partners LLC’s portfolio, making the stock its 8th biggest holding. Riverbridge Partners LLC owned about 0.83% of Medpace worth $114,001,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its position in shares of Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after acquiring an additional 404,226 shares during the period. Arrowstreet Capital Limited Partnership grew its position in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after acquiring an additional 211,411 shares during the period. Franklin Resources Inc. increased its stake in shares of Medpace by 158.6% in the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after purchasing an additional 183,645 shares in the last quarter. Norges Bank purchased a new position in shares of Medpace in the 4th quarter valued at about $102,156,000. Finally, Goldman Sachs Group Inc. raised its holdings in Medpace by 92.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock worth $194,920,000 after purchasing an additional 166,654 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Royal Bank Of Canada dropped their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Robert W. Baird decreased their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Finally, BMO Capital Markets cut their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $467.08.

Medpace Trading Up 3.9%

Shares of Medpace stock opened at $473.48 on Wednesday. Medpace Holdings, Inc. has a twelve month low of $305.69 and a twelve month high of $628.92. The firm has a market capitalization of $13.52 billion, a PE ratio of 29.76, a P/E/G ratio of 2.31 and a beta of 1.18. The firm’s 50-day moving average price is $450.81 and its 200 day moving average price is $497.24.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business’s revenue was up 26.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.